That's a really important question, and it's one worth discussing closely with a hematologist or oncologist who knows the full picture of your situation.
Brukinsa (zanubrutinib) is a targeted therapy that works by blocking a protein called BTK, which WM cells rely on to grow and survive. By doing this, it can help reduce Show Full Answer
That's a really important question, and it's one worth discussing closely with a hematologist or oncologist who knows the full picture of your situation.
Brukinsa (zanubrutinib) is a targeted therapy that works by blocking a protein called BTK, which WM cells rely on to grow and survive. By doing this, it can help reduce IgM levels over time. In clinical studies, many people with WM started seeing IgM reductions within the first few months of treatment, often around 2 to 3 months. However, the full response can continue to deepen over 6 to 12 months or longer.
A few things worth knowing:
- Response times vary from person to person
- Some people respond faster than others
- Regular blood tests are used to track IgM levels and monitor progress
- A partial or major response is still considered a meaningful benefit
It's also worth noting that Brukinsa was more recently FDA-approved specifically for WM, making it a strong option in the treatment lineup. Regular check-ins with your care team will give the clearest picture of how well it's working for you.
AI-generated responses are not a substitute for medical advice. These services are not intended to
diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.
Waldenstrom’s Macroglobulinemia: An Overview
June 13
Join
Your Privacy Choices
